Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-024-06787-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of the safety, biodistribution, dosimetry of [F]AlF-NYM005 and initial experience in clear cell renal cell carcinoma: an interim analysis of a prospective trial.
Eur J Nucl Med Mol Imaging
December 2024
Department of PET-CT, Harbin Medical University Cancer Hospital, Harbin, 150001, China.
Purpose: This first-in-human study aimed to evaluate the radiation dosimetry and whole-body biodistribution of [F]AlF-NYM005, a novel small-molecule carbonic anhydrase IX (CAIX) targeting agent, and to investigate its ability to detect CAIX-positive tumors using PET scans in a cohort of clear cell renal cell carcinoma (ccRCC) patients.
Methods: [F]AlF-NYM005 was synthesized using a fully automatic cassette module Mortenon M1 (Nuoyu, China). Thirty-five patients with a suspicious lesion considered primary renal malignancy or a history of ccRCC were prospectively recruited and studied.
First-in-human Evaluation of Safety and Dosimetry of [Cu]FBP8: A fibrin-binding PET Probe.
Mol Imaging Biol
December 2024
Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, 149 Thirteen St. Suite 2301, Boston, MA, 02129, USA.
Article Synopsis
- - The study investigates the safe use and distribution of a new imaging probe called [Cu]Fibrin Binding Probe #8 ([Cu]FBP8) in healthy individuals, focusing on its potential for thrombus imaging and pulmonary fibrosis detection.
- - Eight participants underwent PET/MRI sessions after receiving the probe, which showed quick blood clearance and renal excretion, with the urinary bladder and kidneys receiving the highest radiation doses.
- - Findings suggest that [Cu]FBP8 has low dosimetry, rapid clearance, and low background signal, making it a promising tool for non-invasive imaging in various medical conditions related to cardiovascular, cancer, and neurological issues.
First-in-human study of Tc-labeled fucoidan, a SPECT tracer targeting P-selectin.
EJNMMI Res
November 2024
Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Article Synopsis
- The study focuses on Tc-fucoidan, a compound derived from brown algae, which targets P-selectin for early identification of thrombosis.
- In the safety assessment involving ten healthy volunteers, Tc-fucoidan was well tolerated with no adverse effects and demonstrated reliable uptake in human thrombi in gamma counting experiments.
- Although the results showed potential for imaging thrombi in certain cases, the overall findings do not support further clinical use of Tc-fucoidan for diagnosing deep vein thrombosis (DVT), suggesting exploration of alternative P-selectin tracers instead.
First-in-human study of dosimetry, safety and efficacy for [Lu]Lu-P15-073: a novel bisphosphonate-based radioligand therapy (RLT) agent for bone metastases.
Eur J Nucl Med Mol Imaging
October 2024
Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, 510120, China.
Article Synopsis
- Bisphosphonates are crucial for treating bone tumors by preventing bone loss; this study explores the effectiveness of a new bisphosphonate, [Lu]Lu-P15-073, in radioligand therapy for bone metastases.
- Ten patients aged 35 to 75 with bone metastases received a single dose of [Lu]Lu-P15-073, showing rapid accumulation in tumors and minimal impact on other organs, while demonstrating safety through blood tests and pain assessments.
- The results indicate that the treatment was well-tolerated, significantly reduced pain in most patients, and suggests that [Lu]Lu-P15-073 could be a promising option for managing bone metastases.
First-in-human study of D6-[F]FP-(+)-DTBZ, a novel VMAT2 tracer: whole-body biodistribution and brain PET comparison with [F]FP-(+)-DTBZ (AV-133).
EJNMMI Radiopharm Chem
October 2024
Department of Nuclear Medicine, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, Guangdong, China.
Article Synopsis
- D6-[F]FP-(+)-DTBZ is a new imaging agent designed for PET scans that helps diagnose Parkinson's disease (PD) by tracking VMAT2 transporters in the brain.
- In a study, this radioligand demonstrated efficient production, high purity, and distinct uptake in brain regions associated with PD, showing a greater effectiveness compared to its non-deuterated counterpart.
- The findings suggest that D6-[F]FP-(+)-DTBZ could serve as a safer, more effective tool for monitoring VMAT2 levels in monoamine neurons, potentially improving PD diagnosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!